DEVELOPMENT AND ESTIMATION OF ANTI-INFLAMMATORY ACTIVITY OF TOPICAL ETORICOXIB EMULGEL BY CARRAGEENAN INDUCED PAW OEDEMA METHOD
Objective: Emulgel is one of the emerging topical drug delivery system for the delivery of hydrophobic drugs which overcome various disadvantages of ointments and creams such as greasiness and phase inversion. Etoricoxib is poorly aqueous soluble Non steroidal Anti-Inflammatory Drug (NSAID). It is used in osteoarthritis, rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, low back pain, acute postoperative pain, and primary dysmenorrheal. Its oral delivery is associated with greater chance of adverse effects or therapeutic failure and large amount of drug is lost in the vicinity of the target organ. Also oral administration of etoricoxib causes gastro-intestinal irritation. The aim of the present study was to develop an emulgel formulations using the gelling agent like Carbopol 934 and HPMC K4M with emulsifiers like Span 20 and Tween 20.
Methods: Six emulgel formulations were developed and evaluated on different parameters like physical appearance, pH, viscosity, extrudability, drug content, spreadability, in-vitro diffusion studies, and skin irritation test.
Results: All trials of emulgel were found to be homogeneous and smears were transparent without grittiness or presence of any particles. The pH values of emulgel batches were found in the range of 6.8-7.1 which is similar to skin pH.
Conclusion: Best formulation of batch EG1 was further evaluated for stability study and anti-inflammatory activity in carrageenan induced rat paw edema. Anti-inflammatory effect of formulation EG1 was compared with standard market product Indomethacin.
Peer Review History:
Received 1 June 2019; Revised 28 June; Accepted 6 July, Available online 15 July 2019
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Average Peer review marks at initial stage: 5.5/10
Average Peer review marks at publication stage: 8.5/10
Name: Dr. Sally A. El-Zahaby
Affiliation: Pharos University in Alexandria, Egypt
Name: Dr. Evren Alğin Yapar
Affiliation: Turkish Medicines and Medical Devices Agency, Turkiye
Comments of reviewer(s):